
R.E. Mendes, H.S. Sader, L.R. Duncan, M. Castanheira, D. Shortridge, R.K. Flamm

JMI Laboratories, North Liberty, Iowa, USA

ABSTRACT

Background. Telavancin has been broadly studied against gram-positive organisms in international surveillance programs. This study evaluates the activity of telavancin against a challenge set of S. aureus isolates from the United States (US) and the rest of the world (ROW).

Methods. 2,558 S. aureus isolates from US and ROW laboratories that had completed telavancin MIC testing were included in the analysis. Clinical and laboratory surveillance programs. This study evaluates the activity of telavancin against a challenge set of S. aureus isolates from the United States (US) and the rest of the world (ROW) (2013–2015). Isolates were also tested for vancomycin and teicoplanin MICs within the M100-S26 method. Vancomycin MICs were reported as ≤0.5 mg/L for S. aureus. All isolates were deemed responsible for human infections per local guidelines. All isolates were tested for teicoplanin MICs using the CLSI-approved method.

RESULTS

- 50.9% of US and 31.5% of ROW isolates were MRSA.
- 95.3% of US MSSA isolates had vancomycin MICs of 0.03 mg/L, whereas 0.5% of US and 0.8% of ROW MSSA isolates had vancomycin MICs of 1.0 mg/L. All MRSA isolates were susceptible to vancomycin (MIC ≤0.03 mg/L).
- Telavancin had consistent MIC activity across US and ROW isolates, with 98.7% of US and 99.4% of ROW isolates susceptible to telavancin (MIC ≤0.03 mg/L).
- Telavancin was also shown to have activity against vancomycin-resistant S. aureus (VRSA) and VISA isolates.

CONCLUSIONS

Telavancin is highly active against S. aureus isolates from both the US and ROW and may provide a valuable therapeutic option given the frequency of MRSA and vancomycin-resistant S. aureus infections.

REFERENCES


ACKNOWLEDGMENTS

The research and publication process was supported by Theravance Biopharma R&D, Inc.

Email: rodrigo-mendes@jmilabs.com

345 Beaver Kreek Centre, Suite A
North Liberty, IA 52253
Ph: (563) 555-5678
Fax: (563) 888-5337
Email: rodrigo-mendes@jmilabs.com

This research and publication process was supported by Theravance Biopharma R&D, Inc.